Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders

Table 2

Mitochondrial respiration and sirtuin 3 (SIRT3) expression/activity in patients with Parkinson’s disease (PD), atypical parkinsonism (AP), and controls (C). Results are presented as mean ± standard deviation (ROUTINE and ROX) and median (interquartile range for LEAK, ETS, and SIRT3). All outcomes of mitochondrial respiration are measured in pmol O2/s10⁶ cells. SIRT3 protein expression is represented as μg/mg protein. SIRT3 activity is represented as U/μg protein.

	Controls (C)	Patients with Parkinson’s disease (PD)	Patients with atypical parkinsonism (AP)	P-PD versus C	P-AP versus C	PD versus AP
ROUTINE; (pmol O2/s10^6 cells)	19.3 ± 4.4	15.2 ± 4.1	15.7 ± 5.3	0.0143	0.644	0.6518
LEAK; (pmol O2/s10^6 cells)	6.02; 5.37–6.78	4.1; 2.97–5.41	4.24; 3.57–6.95	0.0138	0.2665	0.3089
ETS; (pmol O2/s10^6 cells)	13.34; 11.22–17.39	12.03; 9.61–15.45	13.1; 10.56–17.23	0.4171	0.5050	0.4828
ROX; (pmol O2/s10^6 cells)	5.7 ± 1.6	3.75; 2.61–5.52	3.92 ± 1.98	0.0430	0.0754	0.9604
SIRT3 expression; (μg/mg protein)	63.9; 20.5–115.4	37.1; 22.2–59.5	35.4; 24.0–57.9	0.4309	0.5952	0.9429
SIRT3 activity; (U/μg protein)	181.17; 60.9–344.6	66.8; 43.9–111.8	77.4; 30.9–146.2	0.0195	0.0570	0.8312